Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GW5282 plus golidocitinib in T-cell lymphoma
CTR20261011Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GW5282, golidocitinib in T-cell lymphoma, peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
GW5282golidocitinib
03
Conditions
T-cell lymphomaperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20261011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261011.